Biotechnology

The US biotechnology industry has gone through more than three years of sustained IPO financings, but that news isn’t all rosy for the industry.

French biotech consultants Bionest Partners has a system for valuing loss-making biotech companies using information available on a company website.

Who should profit from cutting-edge academic research: the scientists or the institution that funds them? Both, in a new biotech company launched by one of Sweden’s leading researchers.